We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · June 27, 2019

Bevacizumab Does Not Improve Overall Survival in Ovarian Cancer

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
J. Clin. Oncol 2019 Jun 19;[EPub Ahead of Print], KS Tewari, RA Burger, D Enserro, BM Norquist, EM Swisher, MF Brady, MA Bookman, GF Fleming, H Huang, HD Homesley, JM Fowler, BE Greer, M Boente, SX Liang, C Ye, C Bais, LM Randall, JK Chan, JS Ferriss, RL Coleman, C Aghajanian, TJ Herzog, PJ DiSaia, LJ Copeland, RS Mannel, MJ Birrer, BJ Monk

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading